SanMelix Laboratories

Helping You Heal with Honey

SanMelix Laboratories

Helping You Heal with Honey

HOLLYWOOD, FL
Consumer Products
Pharmaceutical
Our Goal is Simple, Faster and Healthier Healing

$202,343

raised
277
Investors
42
Days Left
$0.60
Price per Share
$6.56M
Valuation
Equity
Offering Type
$249.60
Min. Investment

$202,343

raised
277
Investors
42
Days Left
$0.60
Price per Share
$6.56M
Valuation
Equity
Offering Type
$249.60
Min. Investment

Bonus Rewards

Get rewarded for investing more into SanMelix Laboratories

$249+
Investment
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.
$500+
Investment
5% Bonus Shares
If you invest $500+, you will receive 5% bonus shares
$1,000+
Investment
10% Bonus Shares
If you invest $1,000+, you will receive 10% bonus shares
$2,500+
Investment
15% Bonus Shares
If you invest $2,500+, you will receive 15% bonus shares
$5,000+
Investment
20% Bonus Shares
If you invest $5,000+, you will receive 20% bonus shares

Reasons to Invest

First MGO honey-based wound dressing patented formulations with Anticipated FDA microbial claim
U.S. Air force currently performing 510 (k) testing on wound dressing prototype
Our bioactive buckwheat honey products promote faster and healthier healing



Bringing faster healthier healing to all



Invest in SanMelix

Using the natural healing properties of Buckwheat honey, combined with our advanced bioactive enhancements, SanMelix has created a product that aids in the healing of acute, chronic and minor wounds. With IP protection on our BEECure™ MGO dressing and other pending patents, co-created by a renowned Harvard trained podiatric physician, SanMelix's advanced bioactive wound care products can be used in a host of settings and situations. We have created over-the-counter (OTC) skin care products such as ointments and creams designed to help in the healing of minor burns, scrapes, radiodermatitis and more. Our products will also be used for advanced wound care healing in hospitals and rehabilitation centers, by physicians through the use of dressings and ointments.


We have a talented and world-renowned physician group who puts patient care first. Our goal is to improve the lives of patients and help speed up the healing process using the natural therapeutic properties that already exist in honey. Honey has been used in medicine since 8000 BC because of its unique healing properties and with our team of doctors and scientists, we have enhanced it through the use of broad-spectrum antimicrobials. Dr. Sabacinski developed the BEECure™ dressings to help prevent the dangerous side effects and adverse drug interactions that often arise with the use of predominantly synthetic pharmaceuticals. 


Dr. Sabacinski has been working in the wound care space for over thirty years, and he knows the patients’ needs for a product that encourages fast wound closure and provides protection from bacteria and infection. Our mission at SanMelix is to help people. We want to give caregivers, physicians, and the general public the ability to heal using a natural product that’s been used for centuries. At SanMelix, the proof is in the honey. 


With the funds raised through StartEngine, we plan to complete the testing on our products as well as prepare inventory. Our first product launch will be our OTC cosmetic line. We are in negotiations with a European company to license or purchase the CE Marked formulation for our first buckwheat honey skin care product and will use the funds to help complete this arrangement.

The entire population requires wound care



Sources:

*https://www.forbes.com/sites/genemarcial/2014/02/03/overlooked-advanced-wound-care-market-catches-attention-of-healthcare-analysts-investors/#5c53948c48a3

**https://www.grandviewresearch.com/industry-analysis/bioactive-wound-care-market

***https://medbroadcast.com/condition/getcondition/cuts-and-scrapes


But synthetic wound care products have issues


  • Potentially dangerous side effects can occur from entirely synthetic wound care products
  • There are environmental consequences to the manufacturing of chemical based products
  • There are multi drug resistant super infections such as MRSA and A. baumannii*
  • Skin grafts and skin substitutes require repeated application**
  • There are few effective therapies for radiotherapy, laser therapy and minor thermal burns***
  • Often severe wounds can result in amputations


Sources:

*https://www.reuters.com/investigates/special-report/usa-uncounted-cdc/  

**https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4775710/

***https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5677297/

Using natural products we can solve them


  • SanMelix OTC formulations would be considered a first aid antibiotic/antiseptic/antimicrobial to treat minor cuts, scrapes and burns
  • In-vitro findings show that our honey formulations support the efficacy against MRSA and A. baumannii
  • Buckwheat honey reduces scarring and inflammation related to radiotherapy, laser therapy and minor thermal burns
  • Case studies illustrated accelerated healing and skin regeneration on severe limb threatening wounds
  • Need for fewer applications of skin grafts and skin substitute when honey dressings are applied to graft site
  • Studies have shown buckwheat honey has bactericidal activity against antibiotic-resistant pathogens*
  • Greener product in use and in manufacturing


Sources:

*https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5326189/ 

We create products using Buckwheat Honey

We are focusing on the unique medicinal properties of Buckwheat Honey for tissue regeneration and accelerated healing. Our bioactive buckwheat honey formulations demonstrate intrinsic healing activity with anti-microbial additives to prevent infection. SanMelix has a patent on its BEECure™ MGO formulation and Dr. Sabacinski has co-invented 2 additional patent pending natural Buckwheat Honey BEECure™ medical devices which also demonstrated superior clinical outcomes. Studies have proven that buckwheat honey has superior medicinal properties to Manuka honey and other natural remedies. Our products also have higher standardization and broader spectrum anti-microbial activity allowing them to be used on a physician level. Buckwheat honey also has higher anti-inflammatory and anti-oxidant activities than other products currently being used. 


The anti-oxidant properties in Buckwheat honey assist in wound closure and help to stimulate the wound healing process. This means wounds are healing faster and better without the risk of further complications that could be a great hindrance to the lives of patients. The mix of Buckwheat honey with our patented formulation creates a microbial barrier to prevent life-threatening bacteria from penetrating through the dressing while it is in use. The nutrients in the honey help spur tissue regeneration because it contains large quantities of easily assailable sugars, amino acids, vitamins, specifically vitamin C. Our products are made to heal chronic and difficult to close wounds.

Our Products in Use

Our BEECure™ products can be used for a wide variety of skin irritations and advanced wound care. Because of the microbial barrier claim in our wound care dressings, they will be instrumental in the treatment and healing of:

  • Ulcers, diabetic and otherwise
  • Skin grafts
  • Burns
  • Trauma and triage
  • And more!

We are working in tandem with Trauma Insight, who has formed a CRADA with the Airforce, to perform the 510(k) performance and microbial barrier testing. On the battlefield, being able to dress injuries quickly and carefully while keeping bacteria out of the wound is of the utmost importance. Right now, there's an antibiotic-resistant infection that is affecting military personnel overseas. Our dressings create a barrier that will keep the wound clean even in the harshest of conditions.


The advanced wound care MGO dressing is currently in the testing phase, and being tested by the U.S. Air Force. The radiodermatitis cream is in the testing phase for the product and packaging. All other products have not yet been created.

Advanced Wound Care (AWC)

BEECure™ MGO wound dressings

BEECure™ IMelix wound dressings

BEECure™ BMelix wound dressings

Over The Counter (OTC)

BEECure™ RMelix (radiodermatitis)

BEECure ™ Skin Care

BEECure™ Minor Burns

BEECure™ DFU Cream

The difference is in the ingredients

Although manuka honey is the most commonly used honey-based wound treatment on the market, studies have shown that buckwheat honey has superior inherent healing properties when compared to manuka honey due to its higher anti-inflammatory and higher anti-oxidant activities.  In addition, SanMelix’s advanced wound care products have been fortified with antimicrobials to ensure a higher standardized and broader spectrum antibacterial activity. Our patented formulation utilized in our AWC dressings permits SanMelix to launch the first bioactive honey dressing to make a microbial barrier claim in the U.S. Our bioactive dressing will be for any wound type of any depth and severity. The dressing will prevent biofilms from forming,  control wound odor, reduce pain and treatment time while being cost-effective and more environmentally sound. 


Additionally, there will be improved skin and tissue regeneration and debriding action. This prevents the necessity for excess skin grafts or skins substitutes, which run the added risk of infection or rejection. Studies have shown buckwheat honey has bactericidal activity against antibiotic-resistant pathogens.


The bottom line is that our enhanced Buckwheat honey dressings and ointments are making the lives of patients and doctors easier. We are here to assist in the healing process and make a painful experience as painless as possible. We have seen firsthand the need for such products as the ones we've been creating and know that our BEECure™ products are going to be a big step forward in changing the lives of many. 



Natural ingredients that reduce inflammation and rehydrate your skin

Securing powerful partnerships

Through our collaboration with our Contract Research Organization, Trauma Insight, we have been able to establish a collaboration with the Air Force in order to conduct pre-clinical research that will support the 510(k) product testing. Trauma Insight builds on the lessons learned from combat casualty care delivered on the battlefield in Afghanistan and Iraq.


We are looking to continue testing our advanced wound care products to obtain 510(k) pre-market clearance from the FDA and to continue prosecuting our other two patent pending formulation applications. We are in negotiations with a European company to distribute its existing buckwheat honey CE Mark products for radio-dermatitis and laser therapy induced skin reactions and secure our main authentic raw buckwheat honey supplier.


On top of this, we are negotiating with other GMPs to contract manufacture our skin care products. We will continue to test, research and expand our products utilizing world renown physicians and scientists.


We are thrilled about all that lies ahead for the SanMelix team and the effect our nature-based products will have on healing.

A team of experts

SanMelix is proud to have some of the most experienced and widely renowned minds behind our products. Dr. Kenneth Sabacinski has worked in the advanced wound care space for over thirty years. He is a podiatric physician who started his training at Harvard Medical School and Beth Israel Deaconess Medical Center in Boston. People come from all over the world to see him for treatment of limb and life-threatening wounds including diabetic-related foot ulcers.


In addition to co-founder Dr. Sabacinski, our medical team of experts includes Dr. Jason Green, D.O. Board Certified Dermatologist, and COL (ret) George E. Peoples, MD, FACS. Dr. Green is our Advisory Board Director and is currently performing product testing of our initial CE Mark skin care product for radiodermatitis. Dr. George Peoples is the founder of Trauma Insight. Through his military career as a staff surgeon at a level I trauma center and multiple combat deployments, Dr. Peoples has extensive trauma experience and has developed close relationships with some of the most prominent military and civilian trauma and critical care physicians in the country.


Diana Sabacinksi and John Kaufman also serve as directors. Diana has over 25 years of accounting experience across a swath of fields, as well as starting her career in a Big 4 CPA international accounting firm.  John Kaufman is the founder of InteSec Group Fla LLC. He also founded Be Power Tech Inc. and served as its Chairman, Director, co-patent holder, and consultant. Together, the directors boast business acumen and scientific prowess and along with partnerships with other leading researchers and scientists, SanMelix is proud to have such strong and exciting leaders at the helm.

Dr. Kenneth Sabacinski

Diana Sabacinksi

Bringing buckwheat honey's healing power to skin care

Our skin care product line will provide honey based ointment for a myriad conditions like radiodermatitis, rashes, acne and much more. We are currently in the testing phase, running skin irritation and comparative performance tests. Our initial skin care product will be regulated under the United States Federal Food, Drug, and Cosmetic Act. The FDA OTC monograph program will use the patent pending formulations while using already recognized FDA products to enhance our creams and ointments. 

BEECure™ products can be used for or as a(an):

  • Acne Treatment
  • Antiseptic Bandage
  • Diabetic foot cream
  • Burn Care Ointment
  • Radiodermatitis
  • Eczema
  • Eye drops
  • Eczemema
  • Diaper Rash
  • And more!

What people are saying

Help us improve lives

There are over 50 million reported cases globally of patients suffering from hard-to-close wounds. 15% of these are diabetic foot ulcers that eventually lead to amputation. SanMelix BEECure™ bioactive wound care products are here to treat everything from a minor scrape to a severe wound and everything in between. Using our unique enhanced Buckwheat honey formulations fortified with microbial barriers, we are treating all types of dermal afflictions by speeding up the healing process and reducing pain and the risk of infection. 


Honey is a product that's been used all throughout history as a healing and restorative agent, and we are harnessing its natural powers and using our years of scientific and medicinal studies to enhance it. We are regulating it to make it safe for hospital use, as well selling it OTC to the average consumer. Everyone should be able to experience the benefits of the BEECure™ Buckwheat honey products. 


Our customers will include the VA & DoD, medical supply distributors, physician networks, hospitals, SNFs as well as indirect sales channel for private label/ white label for OTC opportunities. We will market directly to OTC consumers through digital marketing and social media. We are capitalizing on a market that has been desperately in need of a natural and safe product that promotes healing and tissue growth among many other benefits. 


We have a talented and world-renowned physician group who puts patient care first. Our goal is to improve patients' lives in need of healing with our innovative bioactive wound care and skin care products.

Offering Summary


Company

:

SanMelix Laboratories, Inc.

Corporate Address

:

1150 North 35th Avenue Suite 225, HOLLYWOOD, FL 33021

Offering Minimum

:

$9,999.60

Offering Maximum

:

$1,069,998.00

Minimum Investment Amount

(per investor)

:

$249.60











Terms


Offering Type

:

Equity

Security Name

:

Common Stock NV

Minimum Number of Shares Offered

:

16,666

Maximum Number of Shares Offered

:

1,783,330

Price per Share

:

$0.60

Pre-Money Valuation

:

$6,561,600.00











*Maximum subject to adjustment for bonus shares. See Bonus info below

Investment Bonuses

If you invest $500+, you will receive 5% bonus shares.

If you invest $1,000+, you will receive 10% bonus shares.

If you invest $2,500+, you will receive 15% bonus shares.

If you invest $5,000+, you will receive 20% bonus shares.

The 10% Bonus for StartEngine Shareholders

SanMelix Laboratories, Inc. will offer 10% additional bonus shares for all investments that are committed by StartEngine Crowdfunding Inc. shareholders who invested over $1,000 in StartEngine's own offerings.

StartEngine shareholders who invested $1,000 or more in any StartEngine offering will receive a 10% bonus on this offering. This means you will receive a bonus for any shares you purchase. For example, if you buy 100 shares of Common Stock NV at $0.60 / share, you will receive 110 Common Stock NV shares, meaning you'll own 110 shares for $60. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% bonus is only valid for one year from the time StartEngine Crowdfunding Inc. investors received their countersigned StartEngine Crowdfunding Inc. subscription agreement.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments.

Show More
Most recent fiscal year-end:
Prior fiscal year-end:
Total Assets
$259,432.00 USD
$437,088.00 USD
Cash And Cash Equivalents
$78,623.00 USD
$298,229.00 USD
Accounts Receivable
$0.00 USD
$0.00 USD
Short Term Debt
$0.00 USD
$0.00 USD
Long Term Debt
$37,200.00 USD
$37,200.00 USD
Revenues And Sales
$0.00 USD
$0.00 USD
Costs Of Goods Sold
$0.00 USD
$0.00 USD
Taxes Paid
$0.00 USD
$0.00 USD
Net Income
-$290,979.00 USD
$0.00 USD

Risks

A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.


Updates

Notice of Material Change in Offering

3 hours ago

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the SanMelix Laboratories offering. Here's an excerpt describing the specifics of the change:


SanMelix Laboratories, Inc. has updated their Board of Directors.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

Surpassed Milestone

8 hours ago

Hey SanMelix Family! 

I hope each and everyone of you enjoyed your thanksgiving weekend!  We wanted to let you know our campaign is doing great.  By the time this update reaches you, we have likely passed our milestone of $200K and getting closer to our $250k goal every day. We regard our investors as valuable contributors to our team, building the SanMelix brand with engagement by sharing our story with friends, family and business contacts. Please help SanMelix get over the next big hump! 

In gratitude,

Diana Sabacinski, CEO

Check Your Email

14 days ago

Hi Everyone, 

We decided to keep the momentum going so we extended our campaign. If you invested recently you should have received an email from StartEngine to reconfirm your investment. Please log back into your account and confirm you are still participating in our journey. We get very excited when we see how many people are investing even just a little bit because they believe in our products and our mission. We again express our appreciation for your confidence and support.

Best regards,

Diana 

CEO SanMelix

The Gift of Healing

16 days ago

Hi Everyone, 

Today we are celebrating that we've reached over 250 investors milestone on our StartEngine campaign! As we are nearing the holiday season, if you haven’t already, join us today and invest in the company that gives the gift of healing. If you have invested, thank you for your support and commitment. 





Notice of Material Change in Offering

24 days ago

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the SanMelix Laboratories offering. Here's an excerpt describing the specifics of the change:


Extended length of campaign.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

Expanding our Story

about 1 month ago

Hello everyone,

Recently Diana Sabacinski, our CEO, was interviewed by CEOCFO magazine. This magazine has been publishing since 2000, and is a brand recognized for their Top Executive interviews. See the article HERE and please share with your network. We've got a few more exciting updates in the lineup so stay tuned. Thank you everyone!



Notice of Funds Disbursement

about 1 month ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, SanMelix Laboratories has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in SanMelix Laboratories be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

New Team Member

about 1 month ago

Hello Everyone,

We are thrilled to announce Randall Carson has joined our team in the role of Director of Reimbursement. Randall’s experience includes Director of Government Affairs & Product Reimbursement at Smith & Nephew, North America, Manager of Product Reimbursement at Covidien and Organogenesis, Inc., and over 20 years’ working in the medical device and biologics industry.  We have reached 200 Investors!! Thank you all so much for your support. Please share our campaign with any friends and family.

Thank you,

The SanMelix Team 

Hand Selected to Present

about 2 months ago

Hi everyone, 

Due to a lot of interest in our company, we are excited to share we were hand selected to present our company at the MicroCap Rodeo in Texas last week. This gave us the opportunity to meet small VCs and high net worth investors. If you have friends that would be interested in SanMelix, please let them know that this is a unique opportunity to get involved!  Stay tuned for our next update.

Best Wishes, 

Diana Sabacinski, CEO

The Holy Grail

about 2 months ago

Hi Everyone,

This week we attended the Military Medical Industry Day in San Antonio, Texas. We met with researchers, developers, and representatives from all three services. During a one on one session they called our dressing “the holy grail” because it contains all three necessary mechanisms for healing. These include debridement, microbial barrier, and skin regeneration. We look forward to working with the DoD in the future to help heal our warfighters. Please continue to share our story and updates with your friends and family.

Sincerely,

The SanMelix Team  

Pink Angel Event

2 months ago

Happy Monday everyone,

In recognition of Breast Cancer Awareness month, we attended the Pink Angels Memorial Foundation fundraising event. These strong group of women raise money to help breast cancer patients in need. It’s our goal to help heal these patients with our radiodermatitis cream.


More updates to come! Don't forget to share our campaign with any friends and family!


Notice of Funds Disbursement

2 months ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, SanMelix Laboratories has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in SanMelix Laboratories be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

October Breast Cancer Awareness Month

2 months ago

 Hello, 

SanMelix is  dedicated to supporting patients battling breast cancer and will be launching the only radiodermatitis cream that uses inherent natural healing properties of Buckwheat Honey (available 2020).  In recognition of breast cancer month, we will be attending the Pink Angels Memorial Foundation event this Thursday, October 3rd. Please help us heal others and continue to share our mission with your network and get them to invest in a company that cares.


 

Up to 150 Investors Today

2 months ago

Today is a very big day for SanMelix. We’ve reached 150 investors! This is an amazing milestone and we wanted to take a second to say thank you for your trust and support.  We've decided to extend the StartEngine campaign for another 60 days to maximize our momentum. A small portion of you, (not all of you), will receive a notice with instructions to reconfirm your investment later today. Please follow the instructions the StartEngine Team sends you so that you can stay apart of this round. 

We have big ambitions for this company. If you haven't joined us yet, now is a great time.

Slam-Dunk Winner

3 months ago

Recently Dr. Jason Green, founder of Green Dermatology and Cosmetic Center in Deerfield Beach, Fla., volunteered to help test our BEECure™ R and had patients with SRT (Superficial Radiotherapy) willing to try it. He says he’s had nothing but success, and it’s going to be a slam-dunk winner.  “It relieves tenderness, itchiness and inflammation as well as redness,” says Green. “It basically soothes the skin. It definitely works and it definitely helps. Please share this exciting news with your network and get them to invest in a company that Heals Others!

Sincerely,

The SanMelix Team

Notice of Material Change in Offering

3 months ago

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the SanMelix Laboratories offering. Here's an excerpt describing the specifics of the change:


Extended length of campaign.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

Notice of Funds Disbursement

3 months ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, SanMelix Laboratories has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in SanMelix Laboratories be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

WOW! We just surpassed 100 Investors. What an Achievement!

4 months ago

What a great month we are having. Surpassed the 100 investor mark and the US Patent and Trademark Office awarded us a patent for our BEECure MGO Advanced Wound Care Dressing.  Great month, great investments. 

Investors who have already contributed please ask your friends and family to invest now! Potential investor, why are you waiting? This is your opportunity to join us and help to heal others.

Sincerely,

The SanMelix Team

Exciting News

4 months ago

Happy Monday, 

Hope you’ve had an amazing summer! We sure did, as we could not be more excited to inform you, our BEECure™ MGO Advanced Wound Care Dressing Patent Was Issued. The patent approval demonstrates the company’s commitment to using robust intellectual property rights to develop visionary consumer, business and medical solutions. This notable achievement allows us to move forward with important initiatives and to speak more openly about our dressings and formulations.  We welcome you to Help Us Heal Others. Please continue to share our story to your network.

Sincerely,

The SanMelix Team

Exciting Milestone Achieved

4 months ago

Dear Shareholders,

Thank you so much for being a part of our crowdfunding campaign! Thanks to you and many others, we reached our equity crowdfunding goal of $107k in under two months. We are in active fundraising mode and continue to build momentum, therefore we made the decision to extend our campaign. We encourage you to share this milestone with others as we believe we have an opportunity to have an important impact on the world. Thank you for your continuous support, and we look forward to the joint path ahead.

Sincerely,

Diana Sabacinski

CEO SanMelix Laboratories, Inc.

Notice of Material Change in Offering

4 months ago

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the SanMelix Laboratories offering. Here's an excerpt describing the specifics of the change:


Sanmelix has has increased their maximum funding goal.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

Notice of Funds Disbursement

4 months ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, SanMelix Laboratories has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in SanMelix Laboratories be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

An In-Depth Article by Health Journal on our Business

4 months ago

We're proud to announce that since launching  our equity crowd-funding campaign in June to help propel BEECure forward, it quickly caught the attention of the publisher at Health Journal.  This award winning publishing company has designed successful marketing and public relations solutions for hundreds of clients. They recently published an editorial featuring SanMelix and our equity crowdfunding campaign. It's a detailed look at our business and what we're looking to achieve. Check out the article at here

 


 

Notice of Funds Disbursement

5 months ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, SanMelix Laboratories has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in SanMelix Laboratories be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Show More Updates End of Updates

Comments ({{profileCtrl.startup.comments_count}} total)

{{profileCtrl.newComment.body.length}}/2500
{{ profileCtrl.commentsLoading ? 'Loading...' : 'Show More Comments' }}